RNAC experienced a dramatic revenue collapse alongside substantially higher losses, while burning through nearly half of its cash position.
The company appears to have transitioned from a revenue-generating entity to a pure R&D operation, with revenue falling to minimal levels while operating losses expanded meaningfully. The substantial cash burn combined with increased R&D spending suggests the company is in an intensive development phase, but the financial runway has shortened considerably.
RNAC's financial profile shifted dramatically, with revenue collapsing to just $2.8M from $38.9M while net losses expanded substantially to $130.3M. The company burned through $87.5M in cash, reducing its position to $125.1M, even as R&D expenses grew 29% to $58.0M, indicating heavy investment in clinical development amid a challenging financial trajectory.
Revenue declined 92.8% — significant demand weakness or market share loss warrants investigation.
Net income declined 68.3% — review whether driven by operations, interest costs, or non-recurring items.
Cash declined 41.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 40.3% — monitor working capital adequacy and short-term liquidity.
Capex reduced 40% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Current liabilities reduced — improved short-term financial position and working capital health.
Total assets contracted 31.9% — asset sales, write-downs, or balance sheet optimization underway.
R&D investment increased 28.7% — signals commitment to future product development, though near-term margin impact.
Receivables grew 27.9% — monitor days sales outstanding for collection efficiency.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →